Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

02 May 2017

  • Continued innovation for market-leading range of fecal management systems for critical care
  • Designed to protect patients and clinicians against over-inflation risk, while helping to reduce risks of skin breakdown and spread of C. difficile infection associated with acute fecal incontinence

READING, UNITED KINGDOM (2 May 2017) — Convatec Group Plc (“Convatec”), a leading global medical technology company, today announced the U.S. launch of the Flexi-Seal™ PROTECT Fecal Management System (FMS), following receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Flexi-Seal™ PROTECT FMS is the latest addition to the company’s market-leading range of advanced systems developed to manage acute fecal incontinence, and help to reduce the associated risks of skin breakdown and spread of C. difficile infection. The new product is designed to provide protection for both patients and clinicians in a number of innovative ways:

  • Fill Protection – the only system that senses when the retention balloon is correctly filled and visually indicates over-inflation.
  • Patient Protection – the blue finger pocket allows easy and accurate placement of the soft silicone retention balloon.
  • Privacy and Odour Protection – the privacy bag lets clinicians monitor volume without compromising patient privacy; and the odour barrier runs the full length of the catheter providing an end-to-end odour barrier.1  

Acute fecal incontinence is a significant issue for hospitals and presents numerous management challenges for clinicians and patients, including an increased risk of pressure injury (pressure ulcer) development as well as the risk of infection spread associated with C. difficile-related diarrhea.

Convatec developed Flexi-Seal™ PROTECT FMS to help clinicians address these many challenges. A temporary containment device indicated for incontinent patients with liquid or semi-liquid stool, Flexi-Seal™ PROTECT FMS is designed to effectively contain and divert fecal matter, and has been proven, in vitro, to contain C. difficile and its spread into the environment.2 The easy-to-use system provides an excellent alternative to traditional methods of managing fecal incontinence such as pads, diapers, fecal pouches and rectal tubes.

“Flexi-Seal™ PROTECT FMS demonstrates our continuing commitment to innovation in critical care, responding to and addressing the needs of customers and patients,” said Mads Haugaard, Vice President and General Manager, Continence and Critical Care, Convatec. “Our goal is to help protect these critically ill patients by minimizing the risks of complications such as skin breakdown and infection spread as well as to help ensure its safe and effective use by the critical care team.”

The U.S. launch of Flexi-Seal™ PROTECT FMS follows the launch of Convatec’s Sensi-Care®  Skin Protectant Incontinence Wipes last month, adding to the company’s comprehensive range of products to help healthcare professionals protect patients’ skin and lessen associated risks such as pressure injury development and infection.

Flexi-Seal™ PROTECT FMS is an indwelling fecal management catheter intended for use to manage fecal incontinence through the collection of liquid to semi-liquid stool and to provide access to administer medications. Following U.S. launch, Flexi-Seal™ PROTECT FMS will be rolled out in additional markets throughout 2017.

For more information, visit www.convatec.com or contact Convatec customer service at 1 (800) 422-8811.

About Convatec

Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Convatec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. www.convatecgroup.com

Enquiries:

Analysts and Investors
John Crosse, VP Investor Relations +44 (0)7500 141435
Kirsty Law, Director Investor Relations +44 (0)7470 909582
investorrelations@convatec.com

Media
Bobby Leach, VP Group Corporate Affairs +44 (0)7770 842226
Finsbury - Rebecca Fitchett +44 (0)207 2513801

 

# # #

Flexi-Seal and Sensi-Care are trademarks of Convatec Inc.
© 2017 Convatec Inc.
AP-017731-US

Download PRESS RELEASE

PDF Download

------------------------------------------------
REFERENCES:
1. Odor Barrier Testing. 130124-001. Data on file, ConvaTec Inc.
2. Jones S, Towers V, Welsby S, et al. Clostridium difficile Containment Properties of a Fecal Management System: An In Vitro Investigation. Ostomy Wound Management 2011;57(10):38–49.

Press Release

See all

5/13/2022

5/13/2022

Organisation Appointments

Organisation Appointments

Read more

5/13/2022

5/13/2022

FY2017 guidance and third quarter update

FY2017 guidance and third quarter update

Read more

5/13/2022

5/13/2022

Convatec Introduces GentleCath™ Glide and me+™ Continence Care Programme for Intermittent Catheter Users in Europe

Convatec Introduces GentleCath™ Glide and me+™ Continence Care Programme for Intermittent Catheter Users in Europe

Read more

5/13/2022

5/13/2022

Scrip Dividend

Scrip Dividend

Read more

5/13/2022

5/13/2022

Appointment to Executive Committee

Appointment to Executive Committee

Read more

5/13/2022

5/13/2022

Convatec appoints two Non-Executive Directors

Convatec appoints two Non-Executive Directors

Read more

8/3/2017

8/3/2017

Convatec Launches Natura™ Convex Accordion Flange™, Designed to Make Ostomy Pouch Application Easier and More Comfortable

Convatec Launches Natura™ Convex Accordion Flange™, Designed to Make Ostomy Pouch Application Easier and More Comfortable

Read more

5/12/2022

5/12/2022

Convatec Announces 2017 Interim results

Convatec Announces 2017 Interim results

Read more

5/12/2022

5/12/2022

03 August 2017 - Board Changes

03 August 2017 - Board Changes

Read more

5/12/2022

5/12/2022

Convatec Announces Acquisition of Woodbury Holdings

Convatec Announces Acquisition of Woodbury Holdings

Read more

5/13/2022

5/13/2022

Announcement on Board of Directors

Announcement on Board of Directors

Read more

5/12/2022

5/12/2022

Trading Update for the three months ended 31 March 2017

Trading Update for the three months ended 31 March 2017

Read more